Response to ‘Rituximab in membranous nephropathy’  by Fervenza, Fernando C. et al.
clearance (t¼3.09, P¼ 0.003) significantly affected the
course of log(proteinuria) (and also proteinuria per se), when
using a comprehensive model. This is in contrast to merely
subjecting the variables to t-tests comparing responders and
nonresponders at two time points. Retreatment, age, stage,
disease duration, and sex were also of minor importance in
the comprehensive model.
Compared to other diseases with surmised immune
pathophysiology, the longevity of the response to rituximab
in membranous nephropathy is amazing. We look forward
to use rituximab to probe into the elusive pathophysiology
of membranous nephropathy. Perhaps optimally analyzed
studies, such as the present study, including urine proteomics
to pinpoint the immune pathophysiology will be feasible
and informative, and supplement conventional, controlled
trials.
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We appreciate Dr Ring’s1 interest in our paper. His
reanalysis using mixed models resulted in a conclusion
similar to our stated results that urine protein decreased
significantly over time for some patients on rituximab.
Further, he found a significant association between base-
line creatinine clearance and urine protein response (when
treated as a quantitative factor). We agree that longitudinal
mixed models are generally more efficient in this setting.
Our small phase 2 trial did not utilize such analyses for
two reasons. One, our analysis was focused on the primary
end point as given in the protocol; 12-month change in
urine protein compared with baseline. This end point was
partly driven by the well-known variations in the natural
history of membranous nephropathy and our feeling that
a treatment effect must endure for at least 12 months to
be considered potentially effective. Protein reductions in
the early post-treatment period followed by increases
(relapses) in later months could result in significant change
in mean slopes for proteinuria but minimal absolute
change at 12 months relative to baseline. The protocol
did include within-patient slopes (using all visits) as a
secondary end point. This analysis (similar in principle to
the mixed models approach) resulted in significant protein
slopes, and the same conclusion was obtained using the
12-month change data, and, as such, it was not included
in the paper. Second, to produce reliable regression
models, it is generally advisable to have at least 10 patients
per predictor variable.2 With only 15 subjects, we felt the
data set was too small to perform comprehensive modeling
with more than one predictor.
We agree with Dr Ring’s observation that prolonged
follow-up is necessary to see the full effect of rituximab
on proteinuria. This may not be unique to rituximab in
this disease. In the trial by Ponticelli et al.3 of methyl-
prednisolone and chlorambucil in membranous nephro-
pathy, few complete remissions occurred during the
6-month treatment phase and almost half occurred at
more than 12 months.
Why some patients respond to rituximab whereas
others do not remains a key question. We agree entirely
with Dr Ring’s statement that this type of study should be
designed and methods used in the analyses should focus
not only on demonstrating potential efficacy but also on
maximizing the information derived by including investi-
gations that may help define the immune pathophysiology
of membranous nephropathy. We are trying to address this
with an ongoing study of rituximab in patients with
membranous nephropathy (http://www.clinicaltrials.gov).
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